Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models

Rheumatology International

Volumn 26, Issue 7, 2006, Pages 627-632

  Yamamoto, Kaname ^a   Yoshino, Shinichi ^a   Shue, Goukei ^a   Nagashima, Masakazu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Etidronate disodium; Interleukin 6; Prostaglandin E2; Rheumatoid arthritis; Substance P

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; DEOXYPYRIDINOLINE; ETIDRONIC ACID; INTERLEUKIN 6; PROSTAGLANDIN E2; SUBSTANCE P;

ANGIOGENESIS; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; ETIDRONIC ACID; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED;

EID: 33645884742     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-005-0042-y     Document Type: Article

References (28)

1. Bromley M, Wooley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in rheumatoid joint. Arthritis Rheum 27:968-975
2. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152:943-951
3. Pearson CM (1956) Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 91:95-101
4. Pearson CM, Wood FD (1963) Studies of arthritis and other lesions induced in rats by the injection of mycobacterial adjuvant. VII. Pathologic details of the arthritis and spondylitis. Am J Pathol 42:73-95
5. Inoue T, Kusida K, Miyamoto S, Sumi Y, Orimo H, Yamashita G (1983) Quantitative assessment of bone density on X-ray picture. J Jpn Orthop 57:1923-1936
6. Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and released conditions by standard reference films. Acta Radiol Diagn 18:481-491
7. Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S (2003) Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 30:474-479
8. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T (1985) Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 28:25-31
9. Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P (1994) Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 53:14-17
10. Haugeberg G, Uhlig T, Falch J, Halse JI, Kvien TK (2004) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Results from 394 patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 3:522-530
11. Suzuki Y, Tanihara M, Ichikawa Y, Osanai A, Nakagawa M, Ide M, Mizushima Y (1994) Periarticular osteopenia in adjuvant-induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells. Ann Rheum Dis 54:484-490
12. Matsuno H, Sawai T, Nezuka T, Uzuki M, Tsuji H, Nishimoto N, Yoshizaki K (1998) Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody; use of rheumatoid arthritis tissue implants in SCID mouse model. Arthritis Rheum 41:2014-2021
13. Suda T, Nakamura I, Jimi E, Takahashi N (1997) Regulation of osteoclast function. J Bone Miner Res 12:869-879
14. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast genesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
15. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801-816
16. Verstraeten A, Dequeker J (1986) Vertebral and peripheral bone mineral content and fracture incidence in post-menopausal patients with rheumatoid arthritis: effet of low dose corticosteroids. Ann Rheum Dis 45:852-857
17. Laan RF, van Riel PL, van Erning LJ, Lemmens JA, Ruijs SH, van de Putte LB (1992) Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol 31:91-96
18. Piet G, Jan D, Johan V, Rita S, Steven B, Jo J, Jo N, Jef R (1998) Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomized placebo controlled study. Ann Rheum Dis 57:724-727
19. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA (1989) Clinical, biochemical, and radiographic effects of aminohydroxypropylidine bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 48:396-399
20. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double blind trial. Arthritis Rheum 39:396-402
21. Heikki V, Leena L, Marja-Kaisa K, Jami M, Claes F, Juha R, Yrjo TK (2003) Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum amino-terminal telopeptides correlate with radiographic progression of disease. J Rheumatol 30:468-473
22. Hirano K (2003) Effects of bisphosphonate on the inflammation. Clin Calcium 2:128-133
23. Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R (1995) Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 44:258-263
24. Tanaka T, Nakayama T, Katsumata T (2001) Therapeutic agent for osteoporosis possessing analgesic effect. Bio Clinica 16:237-241
25. Serre CM, Farlay D, Delmas PD, Chenu C (1999) Evidence for a dense and intimate innervation of bone tissue, including glutamate-containing fibers. Bone 25:623-629
26. Stein C, Millan MJ, Yassouridis A, Herz A (1988) Antinocicetive effects of μ-κ-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur J Pharmacol 155:255-264
27. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI (1984) Intraneuronal substance P contributes to the severity of experimental arthritis. Science 226:547-549
28. Nagashima M, Tanaka H, Takahashi H, Tachihara A, Tanaka K, Ishiwata T, Asano G, Yoshino S (2002) Study of the mechanism involved angiogenesis and synovical cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab Invest 82:981-988